Fluvoxamine, an anti-depressant, inhibits human glioblastoma invasion by disrupting actin polymerization

Glioblastoma multiforme (GBM) is the most common malignant brain tumor with a median survival time about one year. Invasion of GBM cells into normal brain is the major cause of poor prognosis and requires dynamic reorganization of the actin cytoskeleton, which includes lamellipodial protrusions, foc...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Scientific reports 2016-03, Vol.6 (1), p.23372, Article 23372
Hauptverfasser:	Hayashi, Keiichiro, Michiue, Hiroyuki, Yamada, Hiroshi, Takata, Katsuyoshi, Nakayama, Hiroki, Wei, Fan-Yan, Fujimura, Atsushi, Tazawa, Hiroshi, Asai, Akira, Ogo, Naohisa, Miyachi, Hiroyuki, Nishiki, Tei-ichi, Tomizawa, Kazuhito, Takei, Kohji, Matsui, Hideki
Format:	Artikel
Sprache:	eng
Schlagworte:	13/100 45/47 631/154/1435/2417 631/154/152 631/67/1922 631/80/84/2336 64/60 82/47 96/63 Actin AKT protein Animals Antidepressants Blood-brain barrier Brain cancer Brain Neoplasms - drug therapy Brain Neoplasms - metabolism Brain tumors Cell adhesion & migration Cell Line, Tumor Cell migration Cell Movement - drug effects Cytoskeleton Dose-Response Relationship, Drug Drug Repositioning Fibers Fluvoxamine Fluvoxamine - administration & dosage Fluvoxamine - pharmacology Focal adhesion kinase Focal Adhesion Protein-Tyrosine Kinases - metabolism Gene Expression Regulation, Neoplastic - drug effects Glioblastoma Glioblastoma - drug therapy Glioblastoma - metabolism Glioma Glioma cells Humanities and Social Sciences Humans Medical prognosis Mice multidisciplinary Neoplasm Invasiveness Neoplastic Stem Cells - drug effects Polymerization Proto-Oncogene Proteins c-akt - metabolism Pyrene Rapamycin Science Science (multidisciplinary) Serotonin Signal Transduction - drug effects Stem cell transplantation Stem cells Survival Survival Analysis TOR protein TOR Serine-Threonine Kinases - metabolism Toxicity Treatment Outcome Xenograft Model Antitumor Assays
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!